Arvinas, Inc. provided updated guidance for its planned first- and second-line combination clinical trials for vepdegestrant in ER+/HER2- breast cancer. The company plans to initiate a first-line Phase 3 trial combining vepdegestrant with Pfizer’s novel investigational CDK4 inhibitor, atirmociclib, in 2025.
A second-line Phase 3 combination trial, evaluating vepdegestrant with a CDK4/6 inhibitor, is also planned to begin in 2025. The VERITAC-3 trial, which was evaluating vepdegestrant plus palbociclib in the first-line, will not proceed beyond its lead-in phase.
In a corporate update, John Northcott, Chief Commercial Officer, is leaving the company effective January 17, 2025, for personal reasons. Alex Santini, Senior Vice President, Global and U.S. Market Access, has been appointed interim Chief Commercial Officer, effective January 17, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.